Core Viewpoint - The article discusses the upcoming IPO of Shaanxi Maike Aote Pharmaceutical Technology Co., Ltd. on the Hong Kong Stock Exchange, highlighting its status as an unprofitable biotech company with significant losses and a focus on developing peptide drugs [1][3][10]. Company Overview - Shaanxi Maike Aote is co-controlled by professors Wang Bing and Wang Mei from Xi'an Jiaotong University, holding 53% of the company [3][4]. - The company has recently completed a financing round of 236 million RMB, achieving a post-money valuation of 2.636 billion RMB [3]. - The core product, MT1013, targets secondary hyperparathyroidism (SHPT) and is currently in Phase III clinical trials [3][10]. Financial Performance - The company has incurred cumulative losses exceeding 300 million RMB over the past two and a half years, with no product sales revenue to date [3][6]. - Financial data shows that other income for 2023, 2024, and the first half of 2025 was 6.969 million RMB, 4.002 million RMB, and 1.222 million RMB, respectively, primarily from government grants and bank interest [6][7]. - R&D expenses for the same periods were 87.013 million RMB, 107.022 million RMB, and 40.432 million RMB, indicating a high investment typical of biotech firms [8]. Market Potential and Challenges - The company is targeting a market with significant growth potential, with the SHPT drug market projected to reach 14.1 billion RMB by 2035, growing at a CAGR of 20.5%, and the obesity drug market expected to explode to 102.6 billion RMB with a 36.1% annual growth rate [10]. - However, the competitive landscape is intense, with existing players in the SHPT space and major companies dominating the obesity market, posing risks to market share [10][11]. Commercialization Strategy - Maike Aote plans to adopt a dual-track commercialization model involving domestic third-party contract sales organizations (CSO) and international licensing, which aims to minimize initial investment [11]. - The success of this model heavily relies on the capabilities and commitment of partners, making market education and promotion critical for success [11]. Conclusion - The company's journey reflects a broader trend in China's biotech sector, where academic entrepreneurs leverage capital to pursue IPOs despite being unprofitable [11]. - The ability to transition from R&D to commercialization, particularly with the launch of MT1013 in 2028, will be crucial for the company's valuation and market presence [11].

Core Viewpoint - The company, Maikaote Pharmaceutical Technology Co., Ltd., is seeking to list on the Hong Kong Stock Exchange despite being unprofitable, highlighting the trend of biotech firms pursuing capital markets under the 18A listing rules [1][9]. Financial Performance - The company has accumulated losses exceeding 300 million yuan over the past two and a half years, with projected revenues of only 1.22 million yuan in the first half of 2025, reflecting the high investment and long cycle typical of innovative drug companies [2][3][6]. - In 2023, 2024, and the first half of 2025, the company reported other income of 6.969 million yuan, 4.002 million yuan, and 1.222 million yuan, primarily from government subsidies and bank interest, with corresponding losses of 195 million yuan, 157 million yuan, and 49.9 million yuan [6][7]. - As of June 30, 2025, the company held cash and cash equivalents of 107 million yuan, indicating significant cash flow pressure given its average annual losses exceeding 100 million yuan [6][7]. Product Pipeline and Market Potential - The company focuses on a dual-specificity/multi-specificity peptide drug platform, with its core product MT1013 targeting secondary hyperparathyroidism (SHPT) expected to be commercialized by early 2028 [7][8]. - The SHPT drug market in China is projected to reach 14.1 billion yuan by 2035, with a compound annual growth rate (CAGR) of 20.5%, while the obesity drug market is expected to explode to 102.6 billion yuan, growing at a CAGR of 36.1% [8]. Competitive Landscape - The SHPT field has multiple competitors with approved CaSR agonists, and the obesity market is dominated by major players, raising concerns about market share limitations for the company [8]. - The company plans to adopt a dual-track commercialization model involving domestic third-party contract sales organizations (CSO) and international licensing, which relies heavily on the capabilities and investment of partners [8]. Investment and Valuation - The company has achieved a post-financing valuation of 2.636 billion yuan, supported by institutional investors, despite its unprofitability [2][9]. - The shift in investor focus from "story" to "realization" emphasizes the need for a clear commercialization timeline and achievement of research milestones [8][9].